Expression patterns of stromal MMP-2 and tumoural MMP-2 and -9 are significant prognostic factors in invasive ductal carcinoma of the breast

APMIS

Volumn 122, Issue 12, 2014, Pages 1196-1206

  Min, Kyueng Whan ^a   Kim, Dong Hoon ^a   Do, Sung Im ^a   Kim, Kyungeun ^a   Lee, Hyun Joo ^a   Chae, Seoung Wan ^a   Sohn, Jin Hee ^a   Pyo, Jung Soo ^a   Oh, Young Ha ^b   Kim, Wan Seop ^c   Lee, So Young ^c   Oh, Sukjoong ^a   Choi, Seon Hyeong ^a   Park, Yong Lai ^a   Park, Chan Heun ^a  

^a School of Medicine   (South Korea)

^b Hanyang University   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

Author keywords

Breast; Invasive ductal carcinoma; MMP2; MMP9; Stromal cell

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GELATINASE A; GELATINASE B; PROGESTERONE RECEPTOR; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR NECROSIS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84921912941     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12285     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005;93:1046-52.
3. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003;289:1421-4.
4. Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 2009;15:RA32-40.
5. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 2008;26:1-10.
6. Yurchenco PD, Schittny JC. Molecular architecture of basement membranes. FASEB J 1990;4:1577-90.
7. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-14.
8. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
9. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003;200:448-64.
10. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300-8.
11. Sullu Y, Demirag GG, Yildirim A, Karagoz F, Kandemir B. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract 2011;207:747-53.
12. Ishikawa S, Takenaka K, Yanagihara K, Miyahara R, Kawano Y, Otake Y, et al. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res 2004;10:6579-85.
13. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma-tissue immunoreactivity predicts aggressive clinical course. Mod Pathol 2006;19:208-17.
14. Pennanen H, Kuittinen O, Turpeenniemi-Hujanen T. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma. Eur J Haematol 2008;80:46-54.
15. Liao J, Wolfman JC, Wolfman A. K-ras regulates the steady-state expression of matrix metalloproteinase 2 in fibroblasts. J Biol Chem 2003;278:31871-8.
16. Valleala H, Hanemaaijer R, Mandelin J, Salminen A, Teronen O, Monkkonen J, et al. Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sci 2003;73:2413-20.
17. Gonzalez LO, Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez JM, Lamelas ML, et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas. Histopathology 2010;57:862-76.
18. Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Dano K. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest 1997;77:345-55.
19. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19:6642-50.
20. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995;26:873-9.
21. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
22. Feeley LP, Mulligan AM, Pinnaduwage D, Bull SB, Andrulis IL. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol 2014;27:554-61.
23. Del Casar JM, Gonzalez LO, Alvarez E, Junquera S, Marin L, Gonzalez L, et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat 2009;116:39-52.
24. Remmele W. Stegner HE [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Der Pathologe 1987;8:138-40.
25. Stuelten CH. DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 2005;118:2143-53.
26. Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen KJ, Hirtenlehner K, et al. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat 2002;72:69-77.
27. Saad S, Gottlieb DJ, Bradstock KF, Overall CM, Bendall LJ. Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res 2002;62:283-9.
28. Behrens P, Rothe M, Wellmann A, Krischler J, Wernert N. The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol 2001;194:43-50.
29. Schutz A, Schneidenbach D, Aust G, Tannapfel A, Steinert M, Wittekind C. Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumour Biol 2002;23:179-84.
30. Kuittinen O, Apaja-Sarkkinen M, Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas. Eur J Haematol 2003;71:91-9.
31. Vaisanen A, Kuvaja P, Kallioinen M, Turpeenniemi-Hujanen T. A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum Pathol 2011;42:1103-11.
32. Niemiec J, Adamczyk A, Malecki K, Ambicka A, Rys J. Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of st Gallen recommendations. Clin Breast Cancer 2013;13:119-28.
33. Hirvonen R, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res Treat 2003;77:85-91.
34. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003;89:1270-5.
35. McGowan PM, Duffy MJ. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 2008;19:1566-72.
36. Remacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM, et al. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 1998;77:926-31.
37. Mrena J, Wiksten JP, Nordling S, Kokkola A, Ristimaki A, Haglund C. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol 2006;59:618-23.
38. Moser PL, Hefler L, Tempfer C, Neunteufel W, Kieback DG, Gitsch G. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer. Anticancer Res 1999;19:2365-7.
39. Brun JL, Cortez A, Lesieur B, Uzan S, Rouzier R, Darai E. Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. Oncol Rep 2012;27:1049-57.
40. Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 1997;47:461-9.